Patients receiving post-transplant cyclophosphamide to prevent graft-versus-host disease have lower risk for bronchiolitis obliterans syndrome.

After over a decade with HIV, a Norwegian man received a surprise through a stem cell donation from his sibling. The gifted ...

Allogene jumps as cema-cel shows strong MRD clearance and safety in the ALPHA3 study, signaling potential in first-line LBCL ...

Global CAR T-cell Therapy Market OverviewThe global CAR T-cell therapy market is poised for exceptional growth, with an ...

Allogene Therapeutics (NASDAQ:ALLO) detailed interim results from its pivotal Phase II ALPHA3 study during a business update ...

Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that it has acquired an ...

HIV can be controlled but not completely eradicated by current drugs. (Artem_Egorov/iStock/Getty Images Plus) After receiving ...

The honorees are scheduled to deliver lectures during this year’s meeting in San Diego, CA, which runs from April 17-22.

Hospitals can feel overwhelming when you’re going through cancer treatment, which is why many now bring in therapy animals to ...

Cellectis (or the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, ...

Mesoblast offers asymmetric risk-reward with Ryoncil's rapid pediatric SR-aGvHD launch and multiple late-stage pipeline catalysts. Learn why MESO stock is a hold.

Acute myeloid leukemia (AML) has a poor prognosis, especially in elderly and relapsed/refractory patients, with 5‑year survival below 30% ...